GRAIL, Inc. (NASDAQ:GRAL) Given Average Rating of "Hold" by Brokerages

Key Points

• Broker sentiment is mixed on GRAIL, with an average rating of “Hold” from 10 covering firms and an average 1-year target price of $67.00. The breakdown includes one sell, five holds, and four buys.
• Insiders recently sold shares, including CFO Aaron Freidin and CEO Robert P. Ragusa, who together sold more than 169,000 shares in April. Over the last 90 days, insiders have sold 232,464 shares worth about $11.6 million.
• Legal pressure is increasing as multiple law firms urge investors to join a securities fraud class action tied to GRAIL’s NHS-Galleri trial disclosures. The lawsuits allege the company misled investors, with one filing saying the February 20 update erased more than $2.2 billion in market value.

GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) has been assigned an average rating of "Hold" from the ten brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $67.00.

A number of research analysts have commented on the company. The Goldman Sachs Group assumed coverage on GRAIL in a research note on Friday, June 5th. They set a "neutral" rating and a $60.00 price objective on the stock. Wolfe Research assumed coverage on GRAIL in a research note on Tuesday, June 2nd. They set a "peer perform" rating on the stock. Guggenheim reduced their price objective on GRAIL from $130.00 to $75.00 and set a "buy" rating on the stock in a research note on Monday, March 30th. Mizuho assumed coverage on GRAIL in a research note on Friday, April 10th. They set a "neutral" rating and a $58.00 price objective on the stock. Finally, Robert W. Baird set a $70.00 price objective on GRAIL in a research note on Wednesday, May 6th.

Insider Buying and Selling

In other GRAIL news, CFO Aaron Freidin sold 45,806 shares of the business's stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the transaction, the chief financial officer owned 260,669 shares in the company, valued at $13,012,596.48. The trade was a 14.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Robert P. Ragusa sold 123,502 shares of the business's stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total value of $6,165,219.84. Following the transaction, the chief executive officer owned 518,582 shares in the company, valued at approximately $25,887,613.44. This represents a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 232,464 shares of company stock worth $11,621,242. Company insiders own 1.83% of the company's stock.

Institutional Trading of GRAIL

A number of hedge funds and other institutional investors have recently modified their holdings of GRAL. Fifth Third Bancorp increased its position in shares of GRAIL by 15,733.3% during the first quarter. Fifth Third Bancorp now owns 475 shares of the company's stock worth $25,000 after acquiring an additional 472 shares during the last quarter. N.E.W. Advisory Services LLC purchased a new stake in shares of GRAIL during the fourth quarter worth about $26,000. Comerica Bank increased its position in shares of GRAIL by 59.2% during the third quarter. Comerica Bank now owns 465 shares of the company's stock worth $27,000 after acquiring an additional 173 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of GRAIL during the fourth quarter worth about $28,000. Finally, Geneos Wealth Management Inc. increased its position in shares of GRAIL by 160.0% during the first quarter. Geneos Wealth Management Inc. now owns 585 shares of the company's stock worth $30,000 after acquiring an additional 360 shares during the last quarter.

GRAIL Trading Down 1.6%

Shares of GRAL opened at $61.11 on Wednesday. The firm has a market capitalization of $2.62 billion, a P/E ratio of -5.89 and a beta of 3.15. The stock's fifty day simple moving average is $59.70 and its 200 day simple moving average is $72.14. GRAIL has a twelve month low of $29.95 and a twelve month high of $118.84.

GRAIL (NASDAQ:GRAL - Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($2.29) EPS for the quarter, beating the consensus estimate of ($2.76) by $0.47. The company had revenue of $40.79 million for the quarter, compared to analyst estimates of $39.16 million. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%. Sell-side analysts predict that GRAIL will post -10.91 earnings per share for the current year.

Key Headlines Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

• Neutral Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, Glancy Prongay, and others, issued reminders that investors who bought GRAL between May 13, 2025 and February 19, 2026 may join the securities fraud class action, with an August 4, 2026 lead-plaintiff deadline. Article Title
• Neutral Sentiment: The lawsuits allege GRAIL misled investors about its NHS-Galleri trial results, and one filing says the February 20 trial update erased more than $2.2 billion in market value, underscoring the magnitude of the alleged disclosure issue. Article Title
• Negative Sentiment: The mounting legal announcements add to investor uncertainty and could weigh on sentiment toward GRAIL as shareholders await further developments in the class action process. Article Title

About GRAIL

GRAIL, Inc NASDAQ: GRAL is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company's platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.